Original news and analysis on international IP policy
The opinions of the World Health Organization member states on the just-completed election process for a WHO director general showed divisions, according to statements at last week’s meeting of the WHO Executive Board.
The agreement found last year after months of intense discussion to avert the possibility of undue influence by outside actors at the World Health Organization is yet to be fully implemented. The World Health Assembly last week looked at progress and the process by which the WHO can temporarily welcome on its staff individuals from the private sector, civil society, philanthropic foundations, and academic institutions. Some countries questioned principles in this process but were told by the WHO that their comments would merely be recorded.
Cancer, diabetes, heart disease and chronic respiratory diseases are killing millions of people each year, making noncommunicable diseases the leading global cause of human deaths, many of them premature. This week, the World Health Assembly endorsed an updated set of policy options for countries to help them with the prevention and control of those diseases. On the list is a suggestion for tax increases on tobacco products and alcoholic beverages, and the reduction of salt intake. Supported by many countries, it was resisted by the United States and Italy.
After what was described as the biggest World Health Assembly ever, with the highest number of agenda items and the highest attendance, it seemed that all’s well that ends well at the closing ceremony earlier today. A notable fact during this assembly has been the rising volume of voices from developing countries, joined by developed countries on issues related to access to affordable, safe, and efficacious medicines. Resolutions and decisions were adopted, many with hopes of better addressing challenges such as antimicrobial resistance, cancer, substandard and falsified medical products, medicines access and shortages and more.
Does glyphosate, better known under its brand name RoundUp, increase the risk of cancer in humans, or not? Yesterday, some World Health Organization members, while hailing a draft resolution on cancer later adopted, underlined a lack of coordination on glysophate between the WHO and its agency for cancer research. Separately, a renowned scientist sent a letter to European Commission President, Jean-Claude Juncker, saying the evaluations on the herbicide are flawed, and should be done again to safeguard public health.
It is not a mystery, cancer has been spreading for decades, in particular in low and-middle income countries, and is not stopping its course in the foreseeable future. Members of the World Health Organization in committee yesterday adopted a resolution to improve prevention, diagnostics, treatment, and palliative care for cancer, in statements stripped of controversy.
The “delicious acronym SSFFC” - as described by Marie-Paule Kieny, assistant director-general for Health Systems and Innovation at the World Health Organization - will no longer be used by WHO to describe substandard and fake medical products, when a committee's decision is adopted by the full World Health Assembly tomorrow. And key to this decision is that protection of intellectual property rights is not a competence of the UN health agency.
Even though important milestones in the elimination of rubella and measles have been achieved worldwide, key challenges remain, presenters said during a technical briefing organised by the World Health Organization last week.
What if you get an aggressive form of breast cancer, and the treatment exists but it is too expensive for you to get? You die. Tragic stories and the possibilities to avert them were centre stage at a panel last week on the margin of the ongoing World Health Assembly. Delinking the cost of research and development from the market prices of medicines was urged by speakers on the panel: representatives of cancer patients, civil society, and the Brazilian deputy ambassador.
Hopes of stimulating research and development for diseases affecting primarily poor countries and vulnerable populations, through a strategic work plan at the World Health Organization, are dimmed by the lack of funding. An R&D project on a single-dose malaria cure had to be cut short, while a global observatory for health research and development, recently launched, might be hampered in its progress, according to officials.
World Health Assembly Agenda Item 13.5 is descriptively-yet-uninformatively labelled “Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG).” But that anodyne title actually masks an important milestone in the World Health Organization’s long-running efforts to increase R&D around neglected diseases and diseases of poverty.
It is not often that on the matter of access to medicines, India and the United States agree at the World Health Organization. But the issue of access to medicines is rising on the international agenda and developed countries are feeling the bite of prices of new medicines. Core beneficiaries of the patent system held steady this week, but among their defenders, the issue is blurring as some countries, such as the Netherlands, Greece and Portugal, are not putting up with industry prices and are saying it.